Targeting the MAPK/ERK signaling pathway: Mechanistic analysis of pexidartinib in overcoming adriamycin resistance in breast cancer.
- DOI
- 10.1016/j.yexcr.2026.115127
- Published
- 2026 Sep 1
- Container
- Experimental cell research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.yexcr.2026.115127,
title = {Targeting the MAPK/ERK signaling pathway: Mechanistic analysis of pexidartinib in overcoming adriamycin resistance in breast cancer.},
author = {Peng R and Zhan Y and Cheng Z and Li A and Zhou Y and Li Y and Gu Q and Zhu W and Chen S},
year = {2026},
journal = {Experimental cell research},
doi = {10.1016/j.yexcr.2026.115127},
url = {https://doi.org/10.1016/j.yexcr.2026.115127}
}RIS
TY - JOUR TI - Targeting the MAPK/ERK signaling pathway: Mechanistic analysis of pexidartinib in overcoming adriamycin resistance in breast cancer. AU - Peng R AU - Zhan Y AU - Cheng Z AU - Li A AU - Zhou Y AU - Li Y AU - Gu Q AU - Zhu W AU - Chen S PY - 2026 JO - Experimental cell research DO - 10.1016/j.yexcr.2026.115127 UR - https://doi.org/10.1016/j.yexcr.2026.115127 ER -
APA
R, P., Y, Z., Z, C., A, L., Y, Z., Y, L., Q, G., W, Z., & S, C. (2026). Targeting the MAPK/ERK signaling pathway: Mechanistic analysis of pexidartinib in overcoming adriamycin resistance in breast cancer.. Experimental cell research. https://doi.org/10.1016/j.yexcr.2026.115127
Source records
- pubmed · retrieved 2026-09-26T07:55:54.287Z